Clinical significance of minimal residual disease in B-lineage acute lymphoblastic leukemia pediatric patients with different fusion gene backgrounds.
- Author:
Tong WEI
1
;
Xiao-Juan CHEN
1
;
Lu-Yang ZHANG
1
;
Ao-Li ZHANG
1
;
Xiao-Fan ZHU
1
Author Information
1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China.
- Publication Type:Journal Article
- MeSH:
Child;
Core Binding Factor Alpha 2 Subunit;
Disease-Free Survival;
Homeodomain Proteins;
Humans;
Neoplasm, Residual/genetics*;
Oncogene Proteins, Fusion/genetics*;
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/genetics*;
Prognosis;
Retrospective Studies
- From:
Chinese Journal of Contemporary Pediatrics
2020;22(12):1279-1285
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the clinical significance of minimal residual disease (MRD) in B-lineage acute lymphoblastic leukemia (B-ALL) pediatric patients with different fusion gene backgrounds.
METHODS:A retrospective analysis was performed on the medical data of 441 B-ALL children who were treated from January 2008 to April 2015. Among the 441 children, 336 had negative fusion gene, 79 had positive
RESULTS:In patients with negative fusion gene, the positive MRD group had significantly lower overall survival (OS) rate and event-free survival (EFS) rate (
CONCLUSIONS:MRD has the most definite prognostic significance in pediatric B-ALL patients with negative fusion gene, while it has unsatisfactory prognostic significance in those with positive
